Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07739914 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)

Study acronym: ALTERNATION
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Start date changed from estimate of Jun 30, 2026 to Aug 19, 2026
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: details revised at 12 of 18 entries
    • Study description revised
    • Site details revised at 16 of 16 sites
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall aim of this study is nephroprotection based on a calcineurin inhibitor (CNI)-free therapy beyond year one after orthotopic liver transplantation (OLT) in highly pre-selected patients with low rejection risk.
Trial Details
NCT Number NCT07739914
Lead Sponsor Hannover Medical School
Collaborators: Royal Infirmary of Edinburgh
Conditions
(from sponsor)		 Liver Allograft, Liver Diseases, Liver Transplantation
Related terms Hereditary Sensory and Autonomic Neuropathies, Liver Diseases, Rejection, Psychology
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov